

# 11<sup>th</sup> Residential Course on Clinical Pharmacology of Antiretrovirals

*20-22 January 2016*



**Starhotels Majestic,**  
corso Vittorio Emanuele II 54, Turin



# 11<sup>th</sup> Residential Course on Clinical Pharmacology of Antiretrovirals

Starhotels Majestic, corso Vittorio Emanuele II 54, Turin

**20-22 January 2016**

## **COURSE DIRECTOR**

**Prof. Giovanni Di Perri**, Head of the Department of Infectious Diseases, University of Turin, Italy.

## **COURSE SCIENTIFIC SECRETARY**

**Prof. Stefano Bonora**, Department of Infectious Diseases, University of Turin, Italy,

Phone: + 39-011-4393980/4393867, Fax: +39-011-4393882

E-mail: stefano.bonora@unito.it

## **ORGANISING SECRETARIAT**

HealthData Consulting S.r.l.

Via Morghen, 27 Torino - Italy

Phone: +39-011-0267950, Fax: +39-011-0267954

E-mail: segreteria@hdcons.it

## COURSE RATIONALE

The effectiveness of Highly Active Antiretroviral Therapy (HAART) has dramatically changed the life expectancy of HIV-positive individuals. In last years, availability of new drugs and new classes of compounds led to increase therapeutical choices for HIV patients. However, drug development in this field has been particularly rapid, and many issues related to long-term drug efficacy and safety have still to be evaluated in the clinical setting. Moreover, focus on individual needs of HIV patients according to genetic, demographical and clinical characteristics, suggested by a modern viewpoint of management of this longlife treatment, emphasizes the need of personalization and optimization of the regimens.

Under this viewpoint, knowledge of clinical pharmacology of antiretrovirals seems crucial for a modern approach to HIV therapy. A proper use of drugs according to pharmacokinetic and pharmacodynamic properties can maximize the benefits and limit the drawbacks of the treatment.

Recently introduced DAAs mark the beginning of an extraordinary new era in HCV therapy. Updates on this new standard of care is needed, with an emphasis on practical issues related to protease inhibitors, e.g. prescribing guidelines, drug interactions and management of adverse events.

## AIM OF THE COURSE

The aim of the 3-day course is to address the clinicians to a correct management of anti-HIV and anti-HCV therapy based on a sound and comprehensive evaluation of the PK/PD characteristics of antiretroviral drugs. The course contents will consist of lectures, clinical case' presentations, roundtables and plenary discussions in order to stimulate confrontation and improve understanding of critical issues.

## TARGET AUDIENCE AND CME CREDITS

Healthcare professionals who routinely take care of patients with HIV infection.

Provider HealthData Consulting s.r.l. (n.546) has assigned **16 CME credits** according to Italian Health Ministry's criteria.

CME credits will only be awarded to Italian participants who attend the entire course. These categories of health professionals are eligible for CME credit assignment: physicians, hospital pharmacists and biologists.

## FACULTY

- M. Andreoni**, Department of Infectious Diseases, University "Tor Vergata", Rome, Italy.
- A. Antinori**, Department of Infectious Diseases, IRCCS "Lazzaro Spallanzani", Rome Italy.
- D. Back**, Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.
- M. Boffito**, St. Stephen's AIDS Trust, Chelsea and Westminster Hospital, London, UK.
- S. Bonora**, Department of Infectious Diseases, University of Turin, Italy.
- M. Bracchi**, St. Stephen AIDS Trust, Chelsea and Westminster Hospital, London.
- D. Burger**, Department of Pharmacy, Radboud University Medical Center, Nijmegen.
- A. Calcagno**, Department of Infectious Diseases, University of Turin, Italy.
- D. Cattaneo**, Clinical Pharmacology Unit, "Luigi Sacco" Hospital, Milan, Italy.
- F. Ceccherini-Silberstein**, Virology Unit, University "Tor Vergata", Rome, Italy.
- P. Cinque**, Infectious Diseases Unit, Fondazione Centro S. Raffaele Monte Tabor - H.S. Raffaele, Milan, Italy.
- A. D'Avolio**, Department of Infectious Diseases, University of Turin, Italy.
- G. Di Perri**, Department of Infectious Diseases, University of Turin, Italy.
- C. V. Fletcher**, Departments of Pharmacy Practice and Division of Infectious Diseases, Department of Internal Medicine at the University of Nebraska Medical Center, USA.
- M. Galli**, Department of Infectious Diseases, University of Milan, Italy.
- R. Garraffo**, Pharmacology Laboratory, CHU Pasteur, Nice France.
- V. Ghisetti**, Microbiology and Virology Laboratory, Amedeo di Savoia Hospital, Turin, Italy.
- A. Hill**, Pharmacology Research Laboratories, University of Liverpool, UK.
- S. Khoo**, Department of Pharmacology & Therapeutics, University of Liverpool, UK.
- M. Kurowski**, Department of Immunodeficiency Diseases, Ludwig Maximilians University, Berlin, Germany.
- M. Lamorde**, Research Department, Infectious Diseases Institute, Makerere University College of Health Sciences, Kampala, Uganda.
- S. Letendre**, Department of Medicine, University of California San Diego, La Jolla, CA, USA.
- L. Marinaro**, Department of Infectious Diseases, University of Turin, Italy.
- C. Marzolini**, Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, Basel, Switzerland.
- G. Nunnari**, Institute of Infectious Diseases, University of Catania, Italy.
- A. Owen**, Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.
- C. F. Perno**, Virology Unit, University "Tor Vergata", Rome, Italy.
- M. Puoti**, Infectious Diseases Unit, "Niguarda Ca' Granda" Hospital, Milan, Italy.
- M. Rizzetto**, Department of Gastroenterology, University of Turin, Italy.
- J. Rockstroh**, Department of General Internal Medicine, Medical Faculty, University of Bonn, Germany.
- L. Trentini**, Department of Infectious Diseases, University of Turin, Italy.

**20<sup>th</sup> January - AFTERNOON SESSION**

14:15 Welcome and introduction

**CLINICAL PHARMACOLOGY OF HAART (Chair: M. Galli, M. Kurowski)**

14:30 Clinical pharmacology of integrase inhibitors **(M. Boffito)**

15:00 Boosting from ritonavir to cobi **(S. Bonora)**

15:30 Clinical pharmacology of NRTI toxicity: an evolving scenario **(G. Di Perri)**

16:00 Plenary discussion

16:20 Coffee break

16:30 Pharmacological considerations on the use of ARVs in pregnancy **(D. Burger)**

17:00 Clinical notes: TDM of antiretrovirals in 2016 **(L. Marinaro)**

17:30 Role of clinical pharmacology in developing countries **(M. Lamorde)**

18:00 Plenary discussion

18:20 Closing Day 1 Remarks

**21<sup>st</sup> January - MORNING SESSION****LOOKING FORWARD NEW STANDARDS (Chair: M. Andreoni, S. Khoo)**

09:00 Rethinking ARV dosing: PK suggestions and clinical evidence **(A. Hill)**

09:30 Long-acting antiviral agents for HIV treatment **(TBD)**

10:00 Nanoformulations of antivirals **(A. Owen)**

10:30 Pharmacology of generics **(D. Cattaneo)**

11:00 Plenary discussion

11:20 Coffee break

**DRUG-DRUG INTERACTIONS (Chair: R. Garraffo, S. Bonora)**

11:30 Drug-drug interactions in the aging patient **(C. Marzolini)**

12:00 Clinical notes: Chemsex and the new wave of drug-drug interactions **(M. Bracchi)**

12:30 Clinical notes: Management of DDIs in the clinical setting **(L. Trentini)**

13:00 Plenary discussion

13.20 Lunch

## **21<sup>st</sup> January - AFTERNOON SESSION**

### **THE HIDDEN WARS (Chair: G. Di Perri, G. Nunnari)**

- 14:10 HIV beyond plasma viral load **(C. F. Perno)**
- 14:40 Pharmacokinetics and pharmacodynamics in the lymphatic and gut tissues **(C. Fletcher)**
- 15:10 Intracellular penetration of antivirals: facts and myths **(A. D'Avolio)**
- 15:40 Plenary discussion
- 16:00 Coffee break

### **CNS AND HIV/HCV (Chair: A. Antinori)**

- 16:10 Neurocognitive impairment in HCV chronic infection **(S. Letendre)**
- 16:40 Neuroefficacy vs neurotoxicity of ARVs **(A. Calcagno)**
- 17:10 Clinical notes: management of HAART in patients with HAND **(P. Cinque)**
- 17:40 Plenary discussion
- 18:00 Closing Day 2 Remarks

## **22<sup>nd</sup> January - MORNING SESSION**

### **HCV (Chair: M. Rizzetto, V. Ghisetti)**

- 09:00 Who is the difficult-to-treat HCV patient nowadays? **(J. Rockstroh)**
- 09:30 Which role for virologist in DAAs era? **(F. Ceccherini-Silberstein)**
- 10:00 The Clinical Pharmacology of HCV Drugs in Severe Liver Disease **(G. Di Perri)**
- 10:30 Beyond HCV cure: reversibility of liver damage **(M. Puoti)**
- 11:00 Plenary discussion
- 11:20 Coffee break
- 11:30 Drug drug interactions of new HCV drugs **(D. Back)**
- 12:00 Clinica notes: management of the HIV/HCV co-infected patient **(S. Bonora)**
- 12:30 Plenary discussion
- 12:50 Course closing remarks **(G. Di Perri)**
- 13:00 CME test








## COURSE LOCATION and HOTEL ACCOMODATION

**Starhotels Majestic**, corso Vittorio Emanuele II 54, Turin

Tel +39 011 539153 - Fax +39 011 534963



## REGISTRATION INCLUDES

- Admission to all course sessions
- Name tag
- Satchel
- Free onsite wireless
- Catering as per below

| DAY                                   | BREAKFAST    | MORNING BREAK          | LUNCH                  | AFTERNOON BREAK        | DINNER                 |
|---------------------------------------|--------------|------------------------|------------------------|------------------------|------------------------|
| Wednesday<br>20 <sup>th</sup> January | Not included | Not included           | Not included*          | Starhotels<br>Majestic | Starhotels<br>Majestic |
| Thursday<br>21 <sup>st</sup> January  | Not included | Starhotels<br>Majestic | Starhotels<br>Majestic | Starhotels<br>Majestic | Social Dinner          |
| Friday<br>22 <sup>nd</sup> January    | Not included | Starhotels<br>Majestic | Not included**         | Not included           | Not included           |

\* Welcome refreshment

\*\* Light refreshment

The Course offers to all the attendees of the event a Social Dinner atXXXX

Social dinner is free of charge for participants, but is essential to confirm your presence.

In confirming your participation, let us know if you require a vegetarian meal, or if you have any food intolerance or allergies.



*Diamond Sponsor*



*Platinum Sponsor*



*Gold Sponsor*



*Silver Sponsor*

